alexa Cinacalcet HCI (Sensipar Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism.
Pharmaceutical Sciences

Pharmaceutical Sciences

Pharmaceutica Analytica Acta

Author(s): Sterrett JR, Strom J, Stummvoll HK, Bahner U, Disney A,

Abstract Share this page

Abstract AIMS: This 1-year double-blind, placebo-controlled, multicenter study evaluated the long-term safety and efficacy of cinacalcet for the treatment of secondary hyperparathyroidism in patients receiving hemodialysis. METHOD: Patients were randomly assigned in a 1:1 ratio to cinacalcet or control treatment groups. The initial dose of cinacalcet (or matching placebo) was 30 mg. Doses were titrated every 3 or 4 weeks based on the intact parathyroid hormone (iPTH) response and safety profile. Sequential doses included 30, 60, 90, 120 and 180 mg/d. Phosphate binders and vitamin D sterols were adjusted per protocol as needed to control levels of calcium and phosphorus. Efficacy and safety were compared between treatment groups among patients who completed the study (52 total weeks of treatment). Reasons for withdrawal are presented for patients who did not complete the study. RESULTS: A total of 210 patients completed 52 weeks of double-blinded treatment with cinacalcet (n = 99) or placebo (n = 111). Over the last 6 months of the study, a greater proportion of patients in the cinacalcet group than the control group achieved an iPTH level < or = 250 pg/ml (61.6 vs. 9.9\%, p < 0.001) or a > or = 30\% decrease in iPTH from baseline (81.8 vs. 21.6\%, p < 0.001). Mean iPTH levels decreased by -47.8\% in the cinacalcet group and increased by +12.9\% in the control group. Mean percentage changes in other laboratory values in the cinacalcet and control groups included the following: serum calcium -6.5 vs. +0.9\% (p < 0.001), serum phosphorus -3.6 vs. -1.1\% (p = 0.465), and Ca x P -9.9 vs. -0.3\% (p = 0.006). The most commonly reported adverse events related to study drug by the investigators included nausea (13\% cinacalcet, 5\% control), investigator-reported hypocalcemia (11\% cinacalcet, 1\% control), vomiting (9\% cinacalcet, 2\% control), dyspepsia (5\% cinacalcet, 4\% control), and diarrhea (5\% cinacalcet, 2\% control). CONCLUSIONS: Treatment with cinacalcet is a safe and effective therapy for long-term control of secondary hyperparathyroidism. 1-year therapy with cinacalcet was associated with sustained, clinically significant reductions in calcium, Ca x P and iPTH which allowed a greater percentage of patients to achieve NKF-KDOQI target goals for PTH and Ca x P.
This article was published in Clin Nephrol and referenced in Pharmaceutica Analytica Acta

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords